nodes	percent_of_prediction	percent_of_DWPC	metapath
Zuclopenthixol—CYP2D6—Efavirenz—acquired immunodeficiency syndrome	0.0725	0.137	CbGbCtD
Zuclopenthixol—CYP2D6—Nevirapine—acquired immunodeficiency syndrome	0.0682	0.129	CbGbCtD
Zuclopenthixol—CYP2D6—Lopinavir—acquired immunodeficiency syndrome	0.0682	0.129	CbGbCtD
Zuclopenthixol—CYP2D6—Delavirdine—acquired immunodeficiency syndrome	0.0616	0.116	CbGbCtD
Zuclopenthixol—CYP2D6—Amprenavir—acquired immunodeficiency syndrome	0.0616	0.116	CbGbCtD
Zuclopenthixol—CYP2D6—Indinavir—acquired immunodeficiency syndrome	0.0532	0.1	CbGbCtD
Zuclopenthixol—CYP2D6—Nelfinavir—acquired immunodeficiency syndrome	0.0517	0.0974	CbGbCtD
Zuclopenthixol—CYP2D6—Ritonavir—acquired immunodeficiency syndrome	0.0467	0.0881	CbGbCtD
Zuclopenthixol—CYP2D6—Saquinavir—acquired immunodeficiency syndrome	0.0467	0.0881	CbGbCtD
Zuclopenthixol—DRD1—nerve—acquired immunodeficiency syndrome	0.00564	0.0978	CbGeAlD
Zuclopenthixol—DRD2—nerve—acquired immunodeficiency syndrome	0.00333	0.0578	CbGeAlD
Zuclopenthixol—HTR2A—nerve—acquired immunodeficiency syndrome	0.0022	0.0381	CbGeAlD
Zuclopenthixol—DRD5—lymphoid tissue—acquired immunodeficiency syndrome	0.00217	0.0377	CbGeAlD
Zuclopenthixol—ADRA2A—blood plasma—acquired immunodeficiency syndrome	0.00195	0.0339	CbGeAlD
Zuclopenthixol—HTR2A—endothelium—acquired immunodeficiency syndrome	0.00187	0.0325	CbGeAlD
Zuclopenthixol—HTR6—nervous system—acquired immunodeficiency syndrome	0.00171	0.0296	CbGeAlD
Zuclopenthixol—HTR2A—blood plasma—acquired immunodeficiency syndrome	0.00166	0.0288	CbGeAlD
Zuclopenthixol—DRD5—nervous system—acquired immunodeficiency syndrome	0.00166	0.0288	CbGeAlD
Zuclopenthixol—HTR6—central nervous system—acquired immunodeficiency syndrome	0.00164	0.0285	CbGeAlD
Zuclopenthixol—DRD5—central nervous system—acquired immunodeficiency syndrome	0.0016	0.0277	CbGeAlD
Zuclopenthixol—CYP2D6—blood plasma—acquired immunodeficiency syndrome	0.00151	0.0263	CbGeAlD
Zuclopenthixol—DRD2—retina—acquired immunodeficiency syndrome	0.00138	0.0239	CbGeAlD
Zuclopenthixol—HTR6—brain—acquired immunodeficiency syndrome	0.0013	0.0226	CbGeAlD
Zuclopenthixol—DRD5—brain—acquired immunodeficiency syndrome	0.00127	0.022	CbGeAlD
Zuclopenthixol—DRD1—nervous system—acquired immunodeficiency syndrome	0.00127	0.022	CbGeAlD
Zuclopenthixol—DRD1—central nervous system—acquired immunodeficiency syndrome	0.00122	0.0212	CbGeAlD
Zuclopenthixol—ADRA1A—lymphoid tissue—acquired immunodeficiency syndrome	0.001	0.0174	CbGeAlD
Zuclopenthixol—DRD1—brain—acquired immunodeficiency syndrome	0.000969	0.0168	CbGeAlD
Zuclopenthixol—ADRA1A—blood—acquired immunodeficiency syndrome	0.000942	0.0163	CbGeAlD
Zuclopenthixol—HTR2A—retina—acquired immunodeficiency syndrome	0.00091	0.0158	CbGeAlD
Zuclopenthixol—DRD2—lung—acquired immunodeficiency syndrome	0.000809	0.014	CbGeAlD
Zuclopenthixol—HRH1—digestive system—acquired immunodeficiency syndrome	0.000765	0.0133	CbGeAlD
Zuclopenthixol—ADRA1A—nervous system—acquired immunodeficiency syndrome	0.000765	0.0133	CbGeAlD
Zuclopenthixol—DRD2—nervous system—acquired immunodeficiency syndrome	0.000749	0.013	CbGeAlD
Zuclopenthixol—ADRA1A—central nervous system—acquired immunodeficiency syndrome	0.000736	0.0128	CbGeAlD
Zuclopenthixol—DRD2—central nervous system—acquired immunodeficiency syndrome	0.000721	0.0125	CbGeAlD
Zuclopenthixol—ADRA2A—blood—acquired immunodeficiency syndrome	0.000716	0.0124	CbGeAlD
Zuclopenthixol—ADRA2A—spinal cord—acquired immunodeficiency syndrome	0.00069	0.012	CbGeAlD
Zuclopenthixol—HRH1—vagina—acquired immunodeficiency syndrome	0.000676	0.0117	CbGeAlD
Zuclopenthixol—ADRA2A—vagina—acquired immunodeficiency syndrome	0.000664	0.0115	CbGeAlD
Zuclopenthixol—HTR2A—digestive system—acquired immunodeficiency syndrome	0.000639	0.0111	CbGeAlD
Zuclopenthixol—HRH1—lung—acquired immunodeficiency syndrome	0.000639	0.0111	CbGeAlD
Zuclopenthixol—ADRA2A—lung—acquired immunodeficiency syndrome	0.000628	0.0109	CbGeAlD
Zuclopenthixol—HTR2A—blood—acquired immunodeficiency syndrome	0.000609	0.0106	CbGeAlD
Zuclopenthixol—HRH1—nervous system—acquired immunodeficiency syndrome	0.000592	0.0103	CbGeAlD
Zuclopenthixol—HTR2A—spinal cord—acquired immunodeficiency syndrome	0.000587	0.0102	CbGeAlD
Zuclopenthixol—ADRA1A—brain—acquired immunodeficiency syndrome	0.000584	0.0101	CbGeAlD
Zuclopenthixol—CYP2D6—digestive system—acquired immunodeficiency syndrome	0.000582	0.0101	CbGeAlD
Zuclopenthixol—ADRA2A—nervous system—acquired immunodeficiency syndrome	0.000581	0.0101	CbGeAlD
Zuclopenthixol—DRD2—brain—acquired immunodeficiency syndrome	0.000573	0.00994	CbGeAlD
Zuclopenthixol—HRH1—central nervous system—acquired immunodeficiency syndrome	0.00057	0.00988	CbGeAlD
Zuclopenthixol—HTR2A—vagina—acquired immunodeficiency syndrome	0.000564	0.00979	CbGeAlD
Zuclopenthixol—ADRA2A—central nervous system—acquired immunodeficiency syndrome	0.00056	0.00971	CbGeAlD
Zuclopenthixol—CYP2D6—blood—acquired immunodeficiency syndrome	0.000555	0.00962	CbGeAlD
Zuclopenthixol—HTR2A—lung—acquired immunodeficiency syndrome	0.000534	0.00926	CbGeAlD
Zuclopenthixol—HTR2A—nervous system—acquired immunodeficiency syndrome	0.000494	0.00857	CbGeAlD
Zuclopenthixol—HTR2A—central nervous system—acquired immunodeficiency syndrome	0.000476	0.00826	CbGeAlD
Zuclopenthixol—HRH1—brain—acquired immunodeficiency syndrome	0.000452	0.00785	CbGeAlD
Zuclopenthixol—CYP2D6—nervous system—acquired immunodeficiency syndrome	0.00045	0.00781	CbGeAlD
Zuclopenthixol—ADRA2A—brain—acquired immunodeficiency syndrome	0.000444	0.00771	CbGeAlD
Zuclopenthixol—HRH1—lymph node—acquired immunodeficiency syndrome	0.000437	0.00758	CbGeAlD
Zuclopenthixol—CYP2D6—central nervous system—acquired immunodeficiency syndrome	0.000434	0.00752	CbGeAlD
Zuclopenthixol—ADRA2A—lymph node—acquired immunodeficiency syndrome	0.000429	0.00745	CbGeAlD
Zuclopenthixol—HTR2A—brain—acquired immunodeficiency syndrome	0.000378	0.00655	CbGeAlD
Zuclopenthixol—CYP2D6—brain—acquired immunodeficiency syndrome	0.000344	0.00597	CbGeAlD
Zuclopenthixol—Convulsion—Ritonavir—acquired immunodeficiency syndrome	0.00029	0.000783	CcSEcCtD
Zuclopenthixol—Feeling abnormal—Zidovudine—acquired immunodeficiency syndrome	0.00029	0.000782	CcSEcCtD
Zuclopenthixol—Vertigo—Saquinavir—acquired immunodeficiency syndrome	0.000289	0.000782	CcSEcCtD
Zuclopenthixol—Thrombocytopenia—Delavirdine—acquired immunodeficiency syndrome	0.000289	0.000781	CcSEcCtD
Zuclopenthixol—Hypertension—Ritonavir—acquired immunodeficiency syndrome	0.000289	0.00078	CcSEcCtD
Zuclopenthixol—Syncope—Saquinavir—acquired immunodeficiency syndrome	0.000289	0.00078	CcSEcCtD
Zuclopenthixol—Leukopenia—Saquinavir—acquired immunodeficiency syndrome	0.000288	0.000779	CcSEcCtD
Zuclopenthixol—Tachycardia—Delavirdine—acquired immunodeficiency syndrome	0.000288	0.000778	CcSEcCtD
Zuclopenthixol—Tremor—Lamivudine—acquired immunodeficiency syndrome	0.000288	0.000777	CcSEcCtD
Zuclopenthixol—Dyspepsia—Indinavir—acquired immunodeficiency syndrome	0.000288	0.000777	CcSEcCtD
Zuclopenthixol—Gastrointestinal pain—Zidovudine—acquired immunodeficiency syndrome	0.000287	0.000776	CcSEcCtD
Zuclopenthixol—Skin disorder—Delavirdine—acquired immunodeficiency syndrome	0.000287	0.000775	CcSEcCtD
Zuclopenthixol—Pruritus—Nelfinavir—acquired immunodeficiency syndrome	0.000287	0.000775	CcSEcCtD
Zuclopenthixol—Diarrhoea—Nevirapine—acquired immunodeficiency syndrome	0.000286	0.000774	CcSEcCtD
Zuclopenthixol—Pruritus—Stavudine—acquired immunodeficiency syndrome	0.000286	0.000772	CcSEcCtD
Zuclopenthixol—Asthenia—Abacavir—acquired immunodeficiency syndrome	0.000286	0.000772	CcSEcCtD
Zuclopenthixol—Hyperhidrosis—Delavirdine—acquired immunodeficiency syndrome	0.000286	0.000771	CcSEcCtD
Zuclopenthixol—Ill-defined disorder—Lamivudine—acquired immunodeficiency syndrome	0.000285	0.00077	CcSEcCtD
Zuclopenthixol—Myalgia—Ritonavir—acquired immunodeficiency syndrome	0.000285	0.000769	CcSEcCtD
Zuclopenthixol—Decreased appetite—Indinavir—acquired immunodeficiency syndrome	0.000284	0.000767	CcSEcCtD
Zuclopenthixol—Anxiety—Ritonavir—acquired immunodeficiency syndrome	0.000284	0.000767	CcSEcCtD
Zuclopenthixol—Loss of consciousness—Saquinavir—acquired immunodeficiency syndrome	0.000283	0.000765	CcSEcCtD
Zuclopenthixol—Unspecified disorder of skin and subcutaneous tissue—Ritonavir—acquired immunodeficiency syndrome	0.000283	0.000764	CcSEcCtD
Zuclopenthixol—Gastrointestinal disorder—Indinavir—acquired immunodeficiency syndrome	0.000282	0.000762	CcSEcCtD
Zuclopenthixol—Pruritus—Abacavir—acquired immunodeficiency syndrome	0.000282	0.000761	CcSEcCtD
Zuclopenthixol—Fatigue—Indinavir—acquired immunodeficiency syndrome	0.000282	0.000761	CcSEcCtD
Zuclopenthixol—Anorexia—Delavirdine—acquired immunodeficiency syndrome	0.000282	0.00076	CcSEcCtD
Zuclopenthixol—Discomfort—Ritonavir—acquired immunodeficiency syndrome	0.000282	0.00076	CcSEcCtD
Zuclopenthixol—Musculoskeletal discomfort—Efavirenz—acquired immunodeficiency syndrome	0.000281	0.00076	CcSEcCtD
Zuclopenthixol—Pain—Indinavir—acquired immunodeficiency syndrome	0.000279	0.000755	CcSEcCtD
Zuclopenthixol—Constipation—Indinavir—acquired immunodeficiency syndrome	0.000279	0.000755	CcSEcCtD
Zuclopenthixol—Insomnia—Efavirenz—acquired immunodeficiency syndrome	0.000279	0.000754	CcSEcCtD
Zuclopenthixol—Convulsion—Saquinavir—acquired immunodeficiency syndrome	0.000279	0.000754	CcSEcCtD
Zuclopenthixol—Dry mouth—Ritonavir—acquired immunodeficiency syndrome	0.000279	0.000752	CcSEcCtD
Zuclopenthixol—Hypertension—Saquinavir—acquired immunodeficiency syndrome	0.000278	0.000751	CcSEcCtD
Zuclopenthixol—Body temperature increased—Zidovudine—acquired immunodeficiency syndrome	0.000278	0.00075	CcSEcCtD
Zuclopenthixol—Abdominal pain—Zidovudine—acquired immunodeficiency syndrome	0.000278	0.00075	CcSEcCtD
Zuclopenthixol—Diarrhoea—Nelfinavir—acquired immunodeficiency syndrome	0.000277	0.000749	CcSEcCtD
Zuclopenthixol—Paraesthesia—Efavirenz—acquired immunodeficiency syndrome	0.000277	0.000749	CcSEcCtD
Zuclopenthixol—Malaise—Lamivudine—acquired immunodeficiency syndrome	0.000277	0.000748	CcSEcCtD
Zuclopenthixol—Diarrhoea—Stavudine—acquired immunodeficiency syndrome	0.000277	0.000747	CcSEcCtD
Zuclopenthixol—Nausea—Didanosine—acquired immunodeficiency syndrome	0.000277	0.000747	CcSEcCtD
Zuclopenthixol—Vertigo—Lamivudine—acquired immunodeficiency syndrome	0.000276	0.000746	CcSEcCtD
Zuclopenthixol—Hypotension—Delavirdine—acquired immunodeficiency syndrome	0.000276	0.000745	CcSEcCtD
Zuclopenthixol—Syncope—Lamivudine—acquired immunodeficiency syndrome	0.000276	0.000744	CcSEcCtD
Zuclopenthixol—Dyspnoea—Efavirenz—acquired immunodeficiency syndrome	0.000275	0.000743	CcSEcCtD
Zuclopenthixol—Leukopenia—Lamivudine—acquired immunodeficiency syndrome	0.000275	0.000743	CcSEcCtD
Zuclopenthixol—Somnolence—Efavirenz—acquired immunodeficiency syndrome	0.000274	0.000741	CcSEcCtD
Zuclopenthixol—Myalgia—Saquinavir—acquired immunodeficiency syndrome	0.000274	0.000741	CcSEcCtD
Zuclopenthixol—Anxiety—Saquinavir—acquired immunodeficiency syndrome	0.000273	0.000738	CcSEcCtD
Zuclopenthixol—Diarrhoea—Abacavir—acquired immunodeficiency syndrome	0.000272	0.000736	CcSEcCtD
Zuclopenthixol—Unspecified disorder of skin and subcutaneous tissue—Saquinavir—acquired immunodeficiency syndrome	0.000272	0.000735	CcSEcCtD
Zuclopenthixol—Dyspepsia—Efavirenz—acquired immunodeficiency syndrome	0.000272	0.000734	CcSEcCtD
Zuclopenthixol—Discomfort—Saquinavir—acquired immunodeficiency syndrome	0.000271	0.000732	CcSEcCtD
Zuclopenthixol—Loss of consciousness—Lamivudine—acquired immunodeficiency syndrome	0.00027	0.000729	CcSEcCtD
Zuclopenthixol—Feeling abnormal—Indinavir—acquired immunodeficiency syndrome	0.000269	0.000727	CcSEcCtD
Zuclopenthixol—Musculoskeletal discomfort—Delavirdine—acquired immunodeficiency syndrome	0.000269	0.000727	CcSEcCtD
Zuclopenthixol—Shock—Ritonavir—acquired immunodeficiency syndrome	0.000269	0.000726	CcSEcCtD
Zuclopenthixol—Decreased appetite—Efavirenz—acquired immunodeficiency syndrome	0.000268	0.000725	CcSEcCtD
Zuclopenthixol—Dry mouth—Saquinavir—acquired immunodeficiency syndrome	0.000268	0.000724	CcSEcCtD
Zuclopenthixol—Dizziness—Nelfinavir—acquired immunodeficiency syndrome	0.000268	0.000724	CcSEcCtD
Zuclopenthixol—Nervous system disorder—Ritonavir—acquired immunodeficiency syndrome	0.000268	0.000723	CcSEcCtD
Zuclopenthixol—Thrombocytopenia—Ritonavir—acquired immunodeficiency syndrome	0.000267	0.000722	CcSEcCtD
Zuclopenthixol—Dizziness—Stavudine—acquired immunodeficiency syndrome	0.000267	0.000722	CcSEcCtD
Zuclopenthixol—Gastrointestinal pain—Indinavir—acquired immunodeficiency syndrome	0.000267	0.000721	CcSEcCtD
Zuclopenthixol—Insomnia—Delavirdine—acquired immunodeficiency syndrome	0.000267	0.000721	CcSEcCtD
Zuclopenthixol—Tachycardia—Ritonavir—acquired immunodeficiency syndrome	0.000267	0.00072	CcSEcCtD
Zuclopenthixol—Gastrointestinal disorder—Efavirenz—acquired immunodeficiency syndrome	0.000267	0.00072	CcSEcCtD
Zuclopenthixol—Convulsion—Lamivudine—acquired immunodeficiency syndrome	0.000266	0.000719	CcSEcCtD
Zuclopenthixol—Vomiting—Nevirapine—acquired immunodeficiency syndrome	0.000266	0.000719	CcSEcCtD
Zuclopenthixol—Fatigue—Efavirenz—acquired immunodeficiency syndrome	0.000266	0.000719	CcSEcCtD
Zuclopenthixol—Skin disorder—Ritonavir—acquired immunodeficiency syndrome	0.000265	0.000716	CcSEcCtD
Zuclopenthixol—Paraesthesia—Delavirdine—acquired immunodeficiency syndrome	0.000265	0.000716	CcSEcCtD
Zuclopenthixol—Hyperhidrosis—Ritonavir—acquired immunodeficiency syndrome	0.000264	0.000713	CcSEcCtD
Zuclopenthixol—Pain—Efavirenz—acquired immunodeficiency syndrome	0.000264	0.000713	CcSEcCtD
Zuclopenthixol—Constipation—Efavirenz—acquired immunodeficiency syndrome	0.000264	0.000713	CcSEcCtD
Zuclopenthixol—Rash—Nevirapine—acquired immunodeficiency syndrome	0.000264	0.000713	CcSEcCtD
Zuclopenthixol—Dermatitis—Nevirapine—acquired immunodeficiency syndrome	0.000264	0.000712	CcSEcCtD
Zuclopenthixol—Dyspnoea—Delavirdine—acquired immunodeficiency syndrome	0.000263	0.000711	CcSEcCtD
Zuclopenthixol—Dizziness—Abacavir—acquired immunodeficiency syndrome	0.000263	0.000711	CcSEcCtD
Zuclopenthixol—Somnolence—Delavirdine—acquired immunodeficiency syndrome	0.000263	0.000709	CcSEcCtD
Zuclopenthixol—Headache—Nevirapine—acquired immunodeficiency syndrome	0.000262	0.000708	CcSEcCtD
Zuclopenthixol—Myalgia—Lamivudine—acquired immunodeficiency syndrome	0.000262	0.000706	CcSEcCtD
Zuclopenthixol—Anxiety—Lamivudine—acquired immunodeficiency syndrome	0.000261	0.000704	CcSEcCtD
Zuclopenthixol—Anorexia—Ritonavir—acquired immunodeficiency syndrome	0.00026	0.000703	CcSEcCtD
Zuclopenthixol—Dyspepsia—Delavirdine—acquired immunodeficiency syndrome	0.00026	0.000702	CcSEcCtD
Zuclopenthixol—Unspecified disorder of skin and subcutaneous tissue—Lamivudine—acquired immunodeficiency syndrome	0.00026	0.000702	CcSEcCtD
Zuclopenthixol—Shock—Saquinavir—acquired immunodeficiency syndrome	0.000259	0.000698	CcSEcCtD
Zuclopenthixol—Discomfort—Lamivudine—acquired immunodeficiency syndrome	0.000258	0.000698	CcSEcCtD
Zuclopenthixol—Body temperature increased—Indinavir—acquired immunodeficiency syndrome	0.000258	0.000697	CcSEcCtD
Zuclopenthixol—Abdominal pain—Indinavir—acquired immunodeficiency syndrome	0.000258	0.000697	CcSEcCtD
Zuclopenthixol—Nervous system disorder—Saquinavir—acquired immunodeficiency syndrome	0.000258	0.000696	CcSEcCtD
Zuclopenthixol—Vomiting—Nelfinavir—acquired immunodeficiency syndrome	0.000258	0.000696	CcSEcCtD
Zuclopenthixol—Thrombocytopenia—Saquinavir—acquired immunodeficiency syndrome	0.000257	0.000695	CcSEcCtD
Zuclopenthixol—Vomiting—Stavudine—acquired immunodeficiency syndrome	0.000257	0.000694	CcSEcCtD
Zuclopenthixol—Decreased appetite—Delavirdine—acquired immunodeficiency syndrome	0.000257	0.000693	CcSEcCtD
Zuclopenthixol—Dry mouth—Lamivudine—acquired immunodeficiency syndrome	0.000256	0.000691	CcSEcCtD
Zuclopenthixol—Rash—Nelfinavir—acquired immunodeficiency syndrome	0.000256	0.00069	CcSEcCtD
Zuclopenthixol—Dermatitis—Nelfinavir—acquired immunodeficiency syndrome	0.000255	0.00069	CcSEcCtD
Zuclopenthixol—Skin disorder—Saquinavir—acquired immunodeficiency syndrome	0.000255	0.00069	CcSEcCtD
Zuclopenthixol—Hypotension—Ritonavir—acquired immunodeficiency syndrome	0.000255	0.000689	CcSEcCtD
Zuclopenthixol—Gastrointestinal disorder—Delavirdine—acquired immunodeficiency syndrome	0.000255	0.000689	CcSEcCtD
Zuclopenthixol—Rash—Stavudine—acquired immunodeficiency syndrome	0.000255	0.000688	CcSEcCtD
Zuclopenthixol—Fatigue—Delavirdine—acquired immunodeficiency syndrome	0.000255	0.000688	CcSEcCtD
Zuclopenthixol—Dermatitis—Stavudine—acquired immunodeficiency syndrome	0.000255	0.000688	CcSEcCtD
Zuclopenthixol—Feeling abnormal—Efavirenz—acquired immunodeficiency syndrome	0.000254	0.000687	CcSEcCtD
Zuclopenthixol—Hyperhidrosis—Saquinavir—acquired immunodeficiency syndrome	0.000254	0.000686	CcSEcCtD
Zuclopenthixol—Headache—Nelfinavir—acquired immunodeficiency syndrome	0.000254	0.000686	CcSEcCtD
Zuclopenthixol—Headache—Stavudine—acquired immunodeficiency syndrome	0.000253	0.000684	CcSEcCtD
Zuclopenthixol—Vomiting—Abacavir—acquired immunodeficiency syndrome	0.000253	0.000684	CcSEcCtD
Zuclopenthixol—Constipation—Delavirdine—acquired immunodeficiency syndrome	0.000253	0.000682	CcSEcCtD
Zuclopenthixol—Pain—Delavirdine—acquired immunodeficiency syndrome	0.000253	0.000682	CcSEcCtD
Zuclopenthixol—Gastrointestinal pain—Efavirenz—acquired immunodeficiency syndrome	0.000252	0.000682	CcSEcCtD
Zuclopenthixol—Asthenia—Zidovudine—acquired immunodeficiency syndrome	0.000252	0.000681	CcSEcCtD
Zuclopenthixol—Rash—Abacavir—acquired immunodeficiency syndrome	0.000251	0.000678	CcSEcCtD
Zuclopenthixol—Dermatitis—Abacavir—acquired immunodeficiency syndrome	0.000251	0.000677	CcSEcCtD
Zuclopenthixol—Anaphylactic shock—Lamivudine—acquired immunodeficiency syndrome	0.000251	0.000677	CcSEcCtD
Zuclopenthixol—Anorexia—Saquinavir—acquired immunodeficiency syndrome	0.000251	0.000677	CcSEcCtD
Zuclopenthixol—Headache—Abacavir—acquired immunodeficiency syndrome	0.000249	0.000674	CcSEcCtD
Zuclopenthixol—Musculoskeletal discomfort—Ritonavir—acquired immunodeficiency syndrome	0.000249	0.000672	CcSEcCtD
Zuclopenthixol—Nausea—Nevirapine—acquired immunodeficiency syndrome	0.000249	0.000672	CcSEcCtD
Zuclopenthixol—Pruritus—Zidovudine—acquired immunodeficiency syndrome	0.000249	0.000671	CcSEcCtD
Zuclopenthixol—Insomnia—Ritonavir—acquired immunodeficiency syndrome	0.000247	0.000667	CcSEcCtD
Zuclopenthixol—Shock—Lamivudine—acquired immunodeficiency syndrome	0.000247	0.000666	CcSEcCtD
Zuclopenthixol—Nervous system disorder—Lamivudine—acquired immunodeficiency syndrome	0.000246	0.000664	CcSEcCtD
Zuclopenthixol—Hypotension—Saquinavir—acquired immunodeficiency syndrome	0.000246	0.000663	CcSEcCtD
Zuclopenthixol—Thrombocytopenia—Lamivudine—acquired immunodeficiency syndrome	0.000246	0.000663	CcSEcCtD
Zuclopenthixol—Paraesthesia—Ritonavir—acquired immunodeficiency syndrome	0.000245	0.000662	CcSEcCtD
Zuclopenthixol—Abdominal pain—Efavirenz—acquired immunodeficiency syndrome	0.000244	0.000659	CcSEcCtD
Zuclopenthixol—Body temperature increased—Efavirenz—acquired immunodeficiency syndrome	0.000244	0.000659	CcSEcCtD
Zuclopenthixol—Skin disorder—Lamivudine—acquired immunodeficiency syndrome	0.000244	0.000658	CcSEcCtD
Zuclopenthixol—Dyspnoea—Ritonavir—acquired immunodeficiency syndrome	0.000244	0.000658	CcSEcCtD
Zuclopenthixol—Feeling abnormal—Delavirdine—acquired immunodeficiency syndrome	0.000243	0.000657	CcSEcCtD
Zuclopenthixol—Somnolence—Ritonavir—acquired immunodeficiency syndrome	0.000243	0.000656	CcSEcCtD
Zuclopenthixol—Hyperhidrosis—Lamivudine—acquired immunodeficiency syndrome	0.000242	0.000655	CcSEcCtD
Zuclopenthixol—Gastrointestinal pain—Delavirdine—acquired immunodeficiency syndrome	0.000242	0.000652	CcSEcCtD
Zuclopenthixol—Nausea—Nelfinavir—acquired immunodeficiency syndrome	0.000241	0.00065	CcSEcCtD
Zuclopenthixol—Hypersensitivity—Indinavir—acquired immunodeficiency syndrome	0.000241	0.00065	CcSEcCtD
Zuclopenthixol—Dyspepsia—Ritonavir—acquired immunodeficiency syndrome	0.00024	0.000649	CcSEcCtD
Zuclopenthixol—Diarrhoea—Zidovudine—acquired immunodeficiency syndrome	0.00024	0.000649	CcSEcCtD
Zuclopenthixol—Nausea—Stavudine—acquired immunodeficiency syndrome	0.00024	0.000648	CcSEcCtD
Zuclopenthixol—Musculoskeletal discomfort—Saquinavir—acquired immunodeficiency syndrome	0.00024	0.000647	CcSEcCtD
Zuclopenthixol—Anorexia—Lamivudine—acquired immunodeficiency syndrome	0.000239	0.000646	CcSEcCtD
Zuclopenthixol—Insomnia—Saquinavir—acquired immunodeficiency syndrome	0.000238	0.000642	CcSEcCtD
Zuclopenthixol—Decreased appetite—Ritonavir—acquired immunodeficiency syndrome	0.000237	0.000641	CcSEcCtD
Zuclopenthixol—Nausea—Abacavir—acquired immunodeficiency syndrome	0.000237	0.000639	CcSEcCtD
Zuclopenthixol—Paraesthesia—Saquinavir—acquired immunodeficiency syndrome	0.000236	0.000637	CcSEcCtD
Zuclopenthixol—Gastrointestinal disorder—Ritonavir—acquired immunodeficiency syndrome	0.000236	0.000637	CcSEcCtD
Zuclopenthixol—Fatigue—Ritonavir—acquired immunodeficiency syndrome	0.000235	0.000636	CcSEcCtD
Zuclopenthixol—Asthenia—Indinavir—acquired immunodeficiency syndrome	0.000234	0.000633	CcSEcCtD
Zuclopenthixol—Dyspnoea—Saquinavir—acquired immunodeficiency syndrome	0.000234	0.000633	CcSEcCtD
Zuclopenthixol—Hypotension—Lamivudine—acquired immunodeficiency syndrome	0.000234	0.000633	CcSEcCtD
Zuclopenthixol—Somnolence—Saquinavir—acquired immunodeficiency syndrome	0.000234	0.000631	CcSEcCtD
Zuclopenthixol—Constipation—Ritonavir—acquired immunodeficiency syndrome	0.000234	0.000631	CcSEcCtD
Zuclopenthixol—Pain—Ritonavir—acquired immunodeficiency syndrome	0.000234	0.000631	CcSEcCtD
Zuclopenthixol—Body temperature increased—Delavirdine—acquired immunodeficiency syndrome	0.000233	0.000631	CcSEcCtD
Zuclopenthixol—Abdominal pain—Delavirdine—acquired immunodeficiency syndrome	0.000233	0.000631	CcSEcCtD
Zuclopenthixol—Dizziness—Zidovudine—acquired immunodeficiency syndrome	0.000232	0.000627	CcSEcCtD
Zuclopenthixol—Dyspepsia—Saquinavir—acquired immunodeficiency syndrome	0.000231	0.000625	CcSEcCtD
Zuclopenthixol—Pruritus—Indinavir—acquired immunodeficiency syndrome	0.000231	0.000624	CcSEcCtD
Zuclopenthixol—Decreased appetite—Saquinavir—acquired immunodeficiency syndrome	0.000229	0.000617	CcSEcCtD
Zuclopenthixol—Musculoskeletal discomfort—Lamivudine—acquired immunodeficiency syndrome	0.000228	0.000617	CcSEcCtD
Zuclopenthixol—Hypersensitivity—Efavirenz—acquired immunodeficiency syndrome	0.000227	0.000614	CcSEcCtD
Zuclopenthixol—Gastrointestinal disorder—Saquinavir—acquired immunodeficiency syndrome	0.000227	0.000613	CcSEcCtD
Zuclopenthixol—Insomnia—Lamivudine—acquired immunodeficiency syndrome	0.000227	0.000613	CcSEcCtD
Zuclopenthixol—Fatigue—Saquinavir—acquired immunodeficiency syndrome	0.000227	0.000612	CcSEcCtD
Zuclopenthixol—Paraesthesia—Lamivudine—acquired immunodeficiency syndrome	0.000225	0.000608	CcSEcCtD
Zuclopenthixol—Feeling abnormal—Ritonavir—acquired immunodeficiency syndrome	0.000225	0.000608	CcSEcCtD
Zuclopenthixol—Pain—Saquinavir—acquired immunodeficiency syndrome	0.000225	0.000607	CcSEcCtD
Zuclopenthixol—Constipation—Saquinavir—acquired immunodeficiency syndrome	0.000225	0.000607	CcSEcCtD
Zuclopenthixol—Dyspnoea—Lamivudine—acquired immunodeficiency syndrome	0.000224	0.000604	CcSEcCtD
Zuclopenthixol—Diarrhoea—Indinavir—acquired immunodeficiency syndrome	0.000224	0.000604	CcSEcCtD
Zuclopenthixol—Vomiting—Zidovudine—acquired immunodeficiency syndrome	0.000223	0.000603	CcSEcCtD
Zuclopenthixol—Gastrointestinal pain—Ritonavir—acquired immunodeficiency syndrome	0.000223	0.000603	CcSEcCtD
Zuclopenthixol—Somnolence—Lamivudine—acquired immunodeficiency syndrome	0.000223	0.000602	CcSEcCtD
Zuclopenthixol—Rash—Zidovudine—acquired immunodeficiency syndrome	0.000222	0.000598	CcSEcCtD
Zuclopenthixol—Asthenia—Efavirenz—acquired immunodeficiency syndrome	0.000221	0.000598	CcSEcCtD
Zuclopenthixol—Dermatitis—Zidovudine—acquired immunodeficiency syndrome	0.000221	0.000598	CcSEcCtD
Zuclopenthixol—Dyspepsia—Lamivudine—acquired immunodeficiency syndrome	0.000221	0.000596	CcSEcCtD
Zuclopenthixol—Headache—Zidovudine—acquired immunodeficiency syndrome	0.00022	0.000594	CcSEcCtD
Zuclopenthixol—Pruritus—Efavirenz—acquired immunodeficiency syndrome	0.000218	0.00059	CcSEcCtD
Zuclopenthixol—Decreased appetite—Lamivudine—acquired immunodeficiency syndrome	0.000218	0.000589	CcSEcCtD
Zuclopenthixol—Hypersensitivity—Delavirdine—acquired immunodeficiency syndrome	0.000218	0.000588	CcSEcCtD
Zuclopenthixol—Feeling abnormal—Saquinavir—acquired immunodeficiency syndrome	0.000217	0.000585	CcSEcCtD
Zuclopenthixol—Gastrointestinal disorder—Lamivudine—acquired immunodeficiency syndrome	0.000217	0.000585	CcSEcCtD
Zuclopenthixol—Fatigue—Lamivudine—acquired immunodeficiency syndrome	0.000216	0.000584	CcSEcCtD
Zuclopenthixol—Dizziness—Indinavir—acquired immunodeficiency syndrome	0.000216	0.000583	CcSEcCtD
Zuclopenthixol—Abdominal pain—Ritonavir—acquired immunodeficiency syndrome	0.000216	0.000583	CcSEcCtD
Zuclopenthixol—Body temperature increased—Ritonavir—acquired immunodeficiency syndrome	0.000216	0.000583	CcSEcCtD
Zuclopenthixol—Gastrointestinal pain—Saquinavir—acquired immunodeficiency syndrome	0.000215	0.000581	CcSEcCtD
Zuclopenthixol—Pain—Lamivudine—acquired immunodeficiency syndrome	0.000214	0.000579	CcSEcCtD
Zuclopenthixol—Constipation—Lamivudine—acquired immunodeficiency syndrome	0.000214	0.000579	CcSEcCtD
Zuclopenthixol—Asthenia—Delavirdine—acquired immunodeficiency syndrome	0.000212	0.000572	CcSEcCtD
Zuclopenthixol—Diarrhoea—Efavirenz—acquired immunodeficiency syndrome	0.000211	0.00057	CcSEcCtD
Zuclopenthixol—Pruritus—Delavirdine—acquired immunodeficiency syndrome	0.000209	0.000564	CcSEcCtD
Zuclopenthixol—Nausea—Zidovudine—acquired immunodeficiency syndrome	0.000209	0.000564	CcSEcCtD
Zuclopenthixol—Body temperature increased—Saquinavir—acquired immunodeficiency syndrome	0.000208	0.000561	CcSEcCtD
Zuclopenthixol—Abdominal pain—Saquinavir—acquired immunodeficiency syndrome	0.000208	0.000561	CcSEcCtD
Zuclopenthixol—Vomiting—Indinavir—acquired immunodeficiency syndrome	0.000208	0.000561	CcSEcCtD
Zuclopenthixol—Feeling abnormal—Lamivudine—acquired immunodeficiency syndrome	0.000207	0.000558	CcSEcCtD
Zuclopenthixol—Rash—Indinavir—acquired immunodeficiency syndrome	0.000206	0.000556	CcSEcCtD
Zuclopenthixol—Dermatitis—Indinavir—acquired immunodeficiency syndrome	0.000206	0.000556	CcSEcCtD
Zuclopenthixol—Gastrointestinal pain—Lamivudine—acquired immunodeficiency syndrome	0.000205	0.000554	CcSEcCtD
Zuclopenthixol—Headache—Indinavir—acquired immunodeficiency syndrome	0.000205	0.000553	CcSEcCtD
Zuclopenthixol—Dizziness—Efavirenz—acquired immunodeficiency syndrome	0.000204	0.000551	CcSEcCtD
Zuclopenthixol—Diarrhoea—Delavirdine—acquired immunodeficiency syndrome	0.000202	0.000546	CcSEcCtD
Zuclopenthixol—Hypersensitivity—Ritonavir—acquired immunodeficiency syndrome	0.000201	0.000543	CcSEcCtD
Zuclopenthixol—Abdominal pain—Lamivudine—acquired immunodeficiency syndrome	0.000198	0.000535	CcSEcCtD
Zuclopenthixol—Body temperature increased—Lamivudine—acquired immunodeficiency syndrome	0.000198	0.000535	CcSEcCtD
Zuclopenthixol—Vomiting—Efavirenz—acquired immunodeficiency syndrome	0.000196	0.00053	CcSEcCtD
Zuclopenthixol—Asthenia—Ritonavir—acquired immunodeficiency syndrome	0.000196	0.000529	CcSEcCtD
Zuclopenthixol—Dizziness—Delavirdine—acquired immunodeficiency syndrome	0.000195	0.000527	CcSEcCtD
Zuclopenthixol—Rash—Efavirenz—acquired immunodeficiency syndrome	0.000195	0.000526	CcSEcCtD
Zuclopenthixol—Dermatitis—Efavirenz—acquired immunodeficiency syndrome	0.000194	0.000525	CcSEcCtD
Zuclopenthixol—Nausea—Indinavir—acquired immunodeficiency syndrome	0.000194	0.000524	CcSEcCtD
Zuclopenthixol—Hypersensitivity—Saquinavir—acquired immunodeficiency syndrome	0.000194	0.000523	CcSEcCtD
Zuclopenthixol—Headache—Efavirenz—acquired immunodeficiency syndrome	0.000193	0.000522	CcSEcCtD
Zuclopenthixol—Pruritus—Ritonavir—acquired immunodeficiency syndrome	0.000193	0.000522	CcSEcCtD
Zuclopenthixol—Asthenia—Saquinavir—acquired immunodeficiency syndrome	0.000189	0.000509	CcSEcCtD
Zuclopenthixol—Vomiting—Delavirdine—acquired immunodeficiency syndrome	0.000188	0.000507	CcSEcCtD
Zuclopenthixol—Diarrhoea—Ritonavir—acquired immunodeficiency syndrome	0.000187	0.000505	CcSEcCtD
Zuclopenthixol—Rash—Delavirdine—acquired immunodeficiency syndrome	0.000186	0.000503	CcSEcCtD
Zuclopenthixol—Dermatitis—Delavirdine—acquired immunodeficiency syndrome	0.000186	0.000502	CcSEcCtD
Zuclopenthixol—Pruritus—Saquinavir—acquired immunodeficiency syndrome	0.000186	0.000502	CcSEcCtD
Zuclopenthixol—Headache—Delavirdine—acquired immunodeficiency syndrome	0.000185	0.0005	CcSEcCtD
Zuclopenthixol—Hypersensitivity—Lamivudine—acquired immunodeficiency syndrome	0.000185	0.000499	CcSEcCtD
Zuclopenthixol—Nausea—Efavirenz—acquired immunodeficiency syndrome	0.000183	0.000495	CcSEcCtD
Zuclopenthixol—Dizziness—Ritonavir—acquired immunodeficiency syndrome	0.000181	0.000488	CcSEcCtD
Zuclopenthixol—Asthenia—Lamivudine—acquired immunodeficiency syndrome	0.00018	0.000486	CcSEcCtD
Zuclopenthixol—Diarrhoea—Saquinavir—acquired immunodeficiency syndrome	0.00018	0.000486	CcSEcCtD
Zuclopenthixol—Pruritus—Lamivudine—acquired immunodeficiency syndrome	0.000177	0.000479	CcSEcCtD
Zuclopenthixol—Nausea—Delavirdine—acquired immunodeficiency syndrome	0.000175	0.000474	CcSEcCtD
Zuclopenthixol—Dizziness—Saquinavir—acquired immunodeficiency syndrome	0.000174	0.000469	CcSEcCtD
Zuclopenthixol—Vomiting—Ritonavir—acquired immunodeficiency syndrome	0.000174	0.000469	CcSEcCtD
Zuclopenthixol—Rash—Ritonavir—acquired immunodeficiency syndrome	0.000172	0.000465	CcSEcCtD
Zuclopenthixol—Dermatitis—Ritonavir—acquired immunodeficiency syndrome	0.000172	0.000465	CcSEcCtD
Zuclopenthixol—Diarrhoea—Lamivudine—acquired immunodeficiency syndrome	0.000172	0.000463	CcSEcCtD
Zuclopenthixol—Headache—Ritonavir—acquired immunodeficiency syndrome	0.000171	0.000462	CcSEcCtD
Zuclopenthixol—Vomiting—Saquinavir—acquired immunodeficiency syndrome	0.000167	0.000451	CcSEcCtD
Zuclopenthixol—Dizziness—Lamivudine—acquired immunodeficiency syndrome	0.000166	0.000448	CcSEcCtD
Zuclopenthixol—Rash—Saquinavir—acquired immunodeficiency syndrome	0.000166	0.000448	CcSEcCtD
Zuclopenthixol—Dermatitis—Saquinavir—acquired immunodeficiency syndrome	0.000166	0.000447	CcSEcCtD
Zuclopenthixol—Headache—Saquinavir—acquired immunodeficiency syndrome	0.000165	0.000445	CcSEcCtD
Zuclopenthixol—Nausea—Ritonavir—acquired immunodeficiency syndrome	0.000162	0.000438	CcSEcCtD
Zuclopenthixol—Vomiting—Lamivudine—acquired immunodeficiency syndrome	0.000159	0.000431	CcSEcCtD
Zuclopenthixol—Rash—Lamivudine—acquired immunodeficiency syndrome	0.000158	0.000427	CcSEcCtD
Zuclopenthixol—Dermatitis—Lamivudine—acquired immunodeficiency syndrome	0.000158	0.000427	CcSEcCtD
Zuclopenthixol—Headache—Lamivudine—acquired immunodeficiency syndrome	0.000157	0.000424	CcSEcCtD
Zuclopenthixol—Nausea—Saquinavir—acquired immunodeficiency syndrome	0.000156	0.000422	CcSEcCtD
Zuclopenthixol—Nausea—Lamivudine—acquired immunodeficiency syndrome	0.000149	0.000402	CcSEcCtD
Zuclopenthixol—Thioproperazine—ALB—acquired immunodeficiency syndrome	7.31e-05	0.286	CrCbGaD
Zuclopenthixol—Pipotiazine—ALB—acquired immunodeficiency syndrome	7.19e-05	0.281	CrCbGaD
Zuclopenthixol—Thiothixene—ALB—acquired immunodeficiency syndrome	7.19e-05	0.281	CrCbGaD
Zuclopenthixol—HTR6—Signaling Pathways—ACKR1—acquired immunodeficiency syndrome	7.02e-05	0.0017	CbGpPWpGaD
Zuclopenthixol—HTR2A—Class A/1 (Rhodopsin-like receptors)—CCR5—acquired immunodeficiency syndrome	7e-05	0.00169	CbGpPWpGaD
Zuclopenthixol—HRH1—Class A/1 (Rhodopsin-like receptors)—CCR5—acquired immunodeficiency syndrome	6.99e-05	0.00169	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling by GPCR—CCL4—acquired immunodeficiency syndrome	6.99e-05	0.00169	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling by GPCR—ACKR1—acquired immunodeficiency syndrome	6.91e-05	0.00167	CbGpPWpGaD
Zuclopenthixol—HTR6—GPCR downstream signaling—CXCR4—acquired immunodeficiency syndrome	6.87e-05	0.00166	CbGpPWpGaD
Zuclopenthixol—HTR6—GPCR downstream signaling—CXCL12—acquired immunodeficiency syndrome	6.87e-05	0.00166	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling by GPCR—CCL4—acquired immunodeficiency syndrome	6.87e-05	0.00166	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling by GPCR—CCL4—acquired immunodeficiency syndrome	6.86e-05	0.00166	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Class A/1 (Rhodopsin-like receptors)—CCR5—acquired immunodeficiency syndrome	6.86e-05	0.00166	CbGpPWpGaD
Zuclopenthixol—DRD5—GPCR downstream signaling—CCL5—acquired immunodeficiency syndrome	6.78e-05	0.00164	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—CCL3L1—acquired immunodeficiency syndrome	6.74e-05	0.00163	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling by GPCR—CCL4—acquired immunodeficiency syndrome	6.73e-05	0.00163	CbGpPWpGaD
Zuclopenthixol—DRD5—GPCR downstream signaling—CSF2—acquired immunodeficiency syndrome	6.67e-05	0.00161	CbGpPWpGaD
Zuclopenthixol—HTR6—Signaling by GPCR—CCR2—acquired immunodeficiency syndrome	6.64e-05	0.00161	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Class A/1 (Rhodopsin-like receptors)—CCR5—acquired immunodeficiency syndrome	6.37e-05	0.00154	CbGpPWpGaD
Zuclopenthixol—HTR6—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	6.35e-05	0.00153	CbGpPWpGaD
Zuclopenthixol—DRD1—Signaling by GPCR—CCL3—acquired immunodeficiency syndrome	6.32e-05	0.00153	CbGpPWpGaD
Zuclopenthixol—DRD1—GPCR downstream signaling—CCR2—acquired immunodeficiency syndrome	6.29e-05	0.00152	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling by GPCR—CCL4—acquired immunodeficiency syndrome	6.25e-05	0.00151	CbGpPWpGaD
Zuclopenthixol—HTR6—Signaling by GPCR—CXCR4—acquired immunodeficiency syndrome	6.24e-05	0.00151	CbGpPWpGaD
Zuclopenthixol—HTR6—Signaling by GPCR—CXCL12—acquired immunodeficiency syndrome	6.24e-05	0.00151	CbGpPWpGaD
Zuclopenthixol—DRD5—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	6.15e-05	0.00149	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Metabolism—AGPS—acquired immunodeficiency syndrome	6.11e-05	0.00148	CbGpPWpGaD
Zuclopenthixol—DRD5—GPCR downstream signaling—CCR5—acquired immunodeficiency syndrome	6.1e-05	0.00148	CbGpPWpGaD
Zuclopenthixol—DRD5—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	6.06e-05	0.00147	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Hemostasis—IFNA1—acquired immunodeficiency syndrome	6.06e-05	0.00147	CbGpPWpGaD
Zuclopenthixol—DRD1—Signaling Pathways—ACKR1—acquired immunodeficiency syndrome	6.04e-05	0.00146	CbGpPWpGaD
Zuclopenthixol—DRD1—Signaling Pathways—CCNT1—acquired immunodeficiency syndrome	6.04e-05	0.00146	CbGpPWpGaD
Zuclopenthixol—DRD2—GPCR ligand binding—CCL5—acquired immunodeficiency syndrome	6.01e-05	0.00145	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Platelet activation, signaling and aggregation—ALB—acquired immunodeficiency syndrome	6e-05	0.00145	CbGpPWpGaD
Zuclopenthixol—HTR2A—GPCR ligand binding—CCL5—acquired immunodeficiency syndrome	5.92e-05	0.00143	CbGpPWpGaD
Zuclopenthixol—DRD1—GPCR downstream signaling—CXCL12—acquired immunodeficiency syndrome	5.92e-05	0.00143	CbGpPWpGaD
Zuclopenthixol—DRD1—GPCR downstream signaling—CXCR4—acquired immunodeficiency syndrome	5.92e-05	0.00143	CbGpPWpGaD
Zuclopenthixol—HRH1—GPCR ligand binding—CCL5—acquired immunodeficiency syndrome	5.91e-05	0.00143	CbGpPWpGaD
Zuclopenthixol—ADRA1A—GPCR ligand binding—CCL5—acquired immunodeficiency syndrome	5.79e-05	0.0014	CbGpPWpGaD
Zuclopenthixol—DRD1—Signaling by GPCR—CCR2—acquired immunodeficiency syndrome	5.72e-05	0.00138	CbGpPWpGaD
Zuclopenthixol—DRD5—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	5.62e-05	0.00136	CbGpPWpGaD
Zuclopenthixol—DRD5—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	5.54e-05	0.00134	CbGpPWpGaD
Zuclopenthixol—DRD1—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	5.47e-05	0.00132	CbGpPWpGaD
Zuclopenthixol—DRD2—GPCR ligand binding—CCR5—acquired immunodeficiency syndrome	5.42e-05	0.00131	CbGpPWpGaD
Zuclopenthixol—ADRA2A—GPCR ligand binding—CCL5—acquired immunodeficiency syndrome	5.38e-05	0.0013	CbGpPWpGaD
Zuclopenthixol—DRD1—Signaling by GPCR—CXCL12—acquired immunodeficiency syndrome	5.37e-05	0.0013	CbGpPWpGaD
Zuclopenthixol—DRD1—Signaling by GPCR—CXCR4—acquired immunodeficiency syndrome	5.37e-05	0.0013	CbGpPWpGaD
Zuclopenthixol—HTR2A—GPCR ligand binding—CCR5—acquired immunodeficiency syndrome	5.33e-05	0.00129	CbGpPWpGaD
Zuclopenthixol—HRH1—GPCR ligand binding—CCR5—acquired immunodeficiency syndrome	5.32e-05	0.00129	CbGpPWpGaD
Zuclopenthixol—HTR6—GPCR downstream signaling—CCL5—acquired immunodeficiency syndrome	5.23e-05	0.00126	CbGpPWpGaD
Zuclopenthixol—ADRA1A—GPCR ligand binding—CCR5—acquired immunodeficiency syndrome	5.22e-05	0.00126	CbGpPWpGaD
Zuclopenthixol—HTR6—GPCR downstream signaling—CSF2—acquired immunodeficiency syndrome	5.15e-05	0.00125	CbGpPWpGaD
Zuclopenthixol—HTR2A—SIDS Susceptibility Pathways—TNF—acquired immunodeficiency syndrome	5.14e-05	0.00124	CbGpPWpGaD
Zuclopenthixol—DRD5—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	5.08e-05	0.00123	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Platelet activation, signaling and aggregation—IL2—acquired immunodeficiency syndrome	4.86e-05	0.00118	CbGpPWpGaD
Zuclopenthixol—ADRA2A—GPCR ligand binding—CCR5—acquired immunodeficiency syndrome	4.85e-05	0.00117	CbGpPWpGaD
Zuclopenthixol—DRD5—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	4.78e-05	0.00116	CbGpPWpGaD
Zuclopenthixol—DRD5—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	4.78e-05	0.00116	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling by GPCR—CCL3—acquired immunodeficiency syndrome	4.77e-05	0.00115	CbGpPWpGaD
Zuclopenthixol—DRD2—GPCR downstream signaling—CCR2—acquired immunodeficiency syndrome	4.75e-05	0.00115	CbGpPWpGaD
Zuclopenthixol—HTR6—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	4.75e-05	0.00115	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Hemostasis—CSF2—acquired immunodeficiency syndrome	4.74e-05	0.00115	CbGpPWpGaD
Zuclopenthixol—HTR6—GPCR downstream signaling—CCR5—acquired immunodeficiency syndrome	4.71e-05	0.00114	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling by GPCR—CCL3—acquired immunodeficiency syndrome	4.7e-05	0.00114	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling by GPCR—CCL3—acquired immunodeficiency syndrome	4.69e-05	0.00113	CbGpPWpGaD
Zuclopenthixol—CYP2D6—Metabolism—TAT—acquired immunodeficiency syndrome	4.68e-05	0.00113	CbGpPWpGaD
Zuclopenthixol—HTR6—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	4.68e-05	0.00113	CbGpPWpGaD
Zuclopenthixol—HTR2A—GPCR downstream signaling—CCR2—acquired immunodeficiency syndrome	4.68e-05	0.00113	CbGpPWpGaD
Zuclopenthixol—HRH1—GPCR downstream signaling—CCR2—acquired immunodeficiency syndrome	4.67e-05	0.00113	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling by GPCR—CCL3—acquired immunodeficiency syndrome	4.6e-05	0.00111	CbGpPWpGaD
Zuclopenthixol—ADRA1A—GPCR downstream signaling—CCR2—acquired immunodeficiency syndrome	4.58e-05	0.00111	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—CCNT1—acquired immunodeficiency syndrome	4.56e-05	0.0011	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—ACKR1—acquired immunodeficiency syndrome	4.56e-05	0.0011	CbGpPWpGaD
Zuclopenthixol—DRD1—Circadian rythm related genes—IL6—acquired immunodeficiency syndrome	4.56e-05	0.0011	CbGpPWpGaD
Zuclopenthixol—DRD1—GPCR downstream signaling—CCL5—acquired immunodeficiency syndrome	4.5e-05	0.00109	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—ACKR1—acquired immunodeficiency syndrome	4.49e-05	0.00109	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—CCNT1—acquired immunodeficiency syndrome	4.49e-05	0.00109	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—CCNT1—acquired immunodeficiency syndrome	4.48e-05	0.00108	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—ACKR1—acquired immunodeficiency syndrome	4.48e-05	0.00108	CbGpPWpGaD
Zuclopenthixol—DRD2—GPCR downstream signaling—CXCL12—acquired immunodeficiency syndrome	4.47e-05	0.00108	CbGpPWpGaD
Zuclopenthixol—DRD2—GPCR downstream signaling—CXCR4—acquired immunodeficiency syndrome	4.47e-05	0.00108	CbGpPWpGaD
Zuclopenthixol—DRD1—GPCR downstream signaling—CSF2—acquired immunodeficiency syndrome	4.43e-05	0.00107	CbGpPWpGaD
Zuclopenthixol—HTR2A—GPCR downstream signaling—CXCL12—acquired immunodeficiency syndrome	4.4e-05	0.00106	CbGpPWpGaD
Zuclopenthixol—HTR2A—GPCR downstream signaling—CXCR4—acquired immunodeficiency syndrome	4.4e-05	0.00106	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—CCNT1—acquired immunodeficiency syndrome	4.4e-05	0.00106	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—ACKR1—acquired immunodeficiency syndrome	4.4e-05	0.00106	CbGpPWpGaD
Zuclopenthixol—HRH1—GPCR downstream signaling—CXCL12—acquired immunodeficiency syndrome	4.39e-05	0.00106	CbGpPWpGaD
Zuclopenthixol—HRH1—GPCR downstream signaling—CXCR4—acquired immunodeficiency syndrome	4.39e-05	0.00106	CbGpPWpGaD
Zuclopenthixol—HTR6—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	4.34e-05	0.00105	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling by GPCR—CCR2—acquired immunodeficiency syndrome	4.32e-05	0.00104	CbGpPWpGaD
Zuclopenthixol—ADRA1A—GPCR downstream signaling—CXCR4—acquired immunodeficiency syndrome	4.3e-05	0.00104	CbGpPWpGaD
Zuclopenthixol—ADRA1A—GPCR downstream signaling—CXCL12—acquired immunodeficiency syndrome	4.3e-05	0.00104	CbGpPWpGaD
Zuclopenthixol—HTR6—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	4.28e-05	0.00103	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling by GPCR—CCL3—acquired immunodeficiency syndrome	4.27e-05	0.00103	CbGpPWpGaD
Zuclopenthixol—ADRA2A—GPCR downstream signaling—CCR2—acquired immunodeficiency syndrome	4.25e-05	0.00103	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling by GPCR—CCR2—acquired immunodeficiency syndrome	4.25e-05	0.00103	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling by GPCR—CCR2—acquired immunodeficiency syndrome	4.24e-05	0.00102	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling by GPCR—CCR2—acquired immunodeficiency syndrome	4.16e-05	0.00101	CbGpPWpGaD
Zuclopenthixol—HTR2A—SIDS Susceptibility Pathways—IL6—acquired immunodeficiency syndrome	4.15e-05	0.001	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	4.13e-05	0.000998	CbGpPWpGaD
Zuclopenthixol—DRD1—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	4.09e-05	0.000988	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—ACKR1—acquired immunodeficiency syndrome	4.08e-05	0.000987	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—CCNT1—acquired immunodeficiency syndrome	4.08e-05	0.000987	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	4.06e-05	0.000982	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling by GPCR—CXCL12—acquired immunodeficiency syndrome	4.06e-05	0.000981	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling by GPCR—CXCR4—acquired immunodeficiency syndrome	4.06e-05	0.000981	CbGpPWpGaD
Zuclopenthixol—DRD1—GPCR downstream signaling—CCR5—acquired immunodeficiency syndrome	4.06e-05	0.00098	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	4.05e-05	0.000979	CbGpPWpGaD
Zuclopenthixol—DRD1—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	4.03e-05	0.000974	CbGpPWpGaD
Zuclopenthixol—ADRA2A—GPCR downstream signaling—CXCL12—acquired immunodeficiency syndrome	4e-05	0.000967	CbGpPWpGaD
Zuclopenthixol—ADRA2A—GPCR downstream signaling—CXCR4—acquired immunodeficiency syndrome	4e-05	0.000967	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling by GPCR—CXCR4—acquired immunodeficiency syndrome	3.99e-05	0.000965	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling by GPCR—CXCL12—acquired immunodeficiency syndrome	3.99e-05	0.000965	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling by GPCR—CXCR4—acquired immunodeficiency syndrome	3.98e-05	0.000963	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling by GPCR—CXCL12—acquired immunodeficiency syndrome	3.98e-05	0.000963	CbGpPWpGaD
Zuclopenthixol—CYP2D6—Metabolism—AGPS—acquired immunodeficiency syndrome	3.98e-05	0.000963	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	3.98e-05	0.000961	CbGpPWpGaD
Zuclopenthixol—HTR6—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	3.92e-05	0.000948	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling by GPCR—CXCR4—acquired immunodeficiency syndrome	3.91e-05	0.000945	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling by GPCR—CXCL12—acquired immunodeficiency syndrome	3.91e-05	0.000945	CbGpPWpGaD
Zuclopenthixol—Chlorpromazine—ALB—acquired immunodeficiency syndrome	3.9e-05	0.152	CrCbGaD
Zuclopenthixol—ADRA2A—Signaling by GPCR—CCR2—acquired immunodeficiency syndrome	3.86e-05	0.000934	CbGpPWpGaD
Zuclopenthixol—DRD1—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	3.73e-05	0.000903	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	3.69e-05	0.000893	CbGpPWpGaD
Zuclopenthixol—HTR6—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	3.69e-05	0.000892	CbGpPWpGaD
Zuclopenthixol—HTR6—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	3.69e-05	0.000892	CbGpPWpGaD
Zuclopenthixol—DRD1—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	3.68e-05	0.00089	CbGpPWpGaD
Zuclopenthixol—DRD5—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	3.63e-05	0.000879	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling by GPCR—CXCL12—acquired immunodeficiency syndrome	3.63e-05	0.000878	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling by GPCR—CXCR4—acquired immunodeficiency syndrome	3.63e-05	0.000878	CbGpPWpGaD
Zuclopenthixol—DRD5—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	3.58e-05	0.000866	CbGpPWpGaD
Zuclopenthixol—DRD5—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	3.53e-05	0.000853	CbGpPWpGaD
Zuclopenthixol—DRD2—Circadian rythm related genes—IL6—acquired immunodeficiency syndrome	3.44e-05	0.000833	CbGpPWpGaD
Zuclopenthixol—DRD2—GPCR downstream signaling—CCL5—acquired immunodeficiency syndrome	3.4e-05	0.000822	CbGpPWpGaD
Zuclopenthixol—DRD1—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	3.38e-05	0.000816	CbGpPWpGaD
Zuclopenthixol—DRD2—GPCR downstream signaling—CSF2—acquired immunodeficiency syndrome	3.35e-05	0.000809	CbGpPWpGaD
Zuclopenthixol—HTR2A—GPCR downstream signaling—CCL5—acquired immunodeficiency syndrome	3.34e-05	0.000809	CbGpPWpGaD
Zuclopenthixol—HRH1—GPCR downstream signaling—CCL5—acquired immunodeficiency syndrome	3.34e-05	0.000807	CbGpPWpGaD
Zuclopenthixol—HTR2A—GPCR downstream signaling—CSF2—acquired immunodeficiency syndrome	3.29e-05	0.000796	CbGpPWpGaD
Zuclopenthixol—HRH1—GPCR downstream signaling—CSF2—acquired immunodeficiency syndrome	3.29e-05	0.000795	CbGpPWpGaD
Zuclopenthixol—ADRA1A—GPCR downstream signaling—CCL5—acquired immunodeficiency syndrome	3.27e-05	0.000792	CbGpPWpGaD
Zuclopenthixol—DRD5—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	3.27e-05	0.000792	CbGpPWpGaD
Zuclopenthixol—ADRA1A—GPCR downstream signaling—CSF2—acquired immunodeficiency syndrome	3.23e-05	0.00078	CbGpPWpGaD
Zuclopenthixol—HTR2A—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—acquired immunodeficiency syndrome	3.21e-05	0.000776	CbGpPWpGaD
Zuclopenthixol—HRH1—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—acquired immunodeficiency syndrome	3.2e-05	0.000775	CbGpPWpGaD
Zuclopenthixol—DRD5—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	3.2e-05	0.000774	CbGpPWpGaD
Zuclopenthixol—DRD1—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	3.17e-05	0.000767	CbGpPWpGaD
Zuclopenthixol—DRD1—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	3.17e-05	0.000767	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—acquired immunodeficiency syndrome	3.14e-05	0.00076	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Hemostasis—ALB—acquired immunodeficiency syndrome	3.09e-05	0.000747	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	3.09e-05	0.000746	CbGpPWpGaD
Zuclopenthixol—DRD2—GPCR downstream signaling—CCR5—acquired immunodeficiency syndrome	3.06e-05	0.00074	CbGpPWpGaD
Zuclopenthixol—ADRA2A—GPCR downstream signaling—CCL5—acquired immunodeficiency syndrome	3.04e-05	0.000736	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	3.04e-05	0.000735	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	3.04e-05	0.000734	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	3.03e-05	0.000733	CbGpPWpGaD
Zuclopenthixol—HTR2A—GPCR downstream signaling—CCR5—acquired immunodeficiency syndrome	3.01e-05	0.000728	CbGpPWpGaD
Zuclopenthixol—HRH1—GPCR downstream signaling—CCR5—acquired immunodeficiency syndrome	3.01e-05	0.000727	CbGpPWpGaD
Zuclopenthixol—ADRA2A—GPCR downstream signaling—CSF2—acquired immunodeficiency syndrome	3e-05	0.000725	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	2.99e-05	0.000723	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	2.99e-05	0.000722	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	2.97e-05	0.000719	CbGpPWpGaD
Zuclopenthixol—ADRA1A—GPCR downstream signaling—CCR5—acquired immunodeficiency syndrome	2.95e-05	0.000713	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	2.93e-05	0.000708	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	2.82e-05	0.000681	CbGpPWpGaD
Zuclopenthixol—HTR6—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	2.81e-05	0.000678	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	2.78e-05	0.000672	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	2.77e-05	0.000671	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	2.77e-05	0.000669	CbGpPWpGaD
Zuclopenthixol—HTR6—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	2.76e-05	0.000668	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	2.76e-05	0.000668	CbGpPWpGaD
Zuclopenthixol—ADRA2A—GPCR downstream signaling—CCR5—acquired immunodeficiency syndrome	2.74e-05	0.000663	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	2.74e-05	0.000661	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	2.73e-05	0.00066	CbGpPWpGaD
Zuclopenthixol—HTR6—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	2.72e-05	0.000658	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	2.72e-05	0.000658	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	2.72e-05	0.000657	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	2.68e-05	0.000648	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	2.55e-05	0.000616	CbGpPWpGaD
Zuclopenthixol—HTR6—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	2.53e-05	0.000611	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	2.52e-05	0.00061	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	2.51e-05	0.000606	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Hemostasis—IL2—acquired immunodeficiency syndrome	2.51e-05	0.000606	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	2.5e-05	0.000605	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	2.49e-05	0.000602	CbGpPWpGaD
Zuclopenthixol—HTR6—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	2.47e-05	0.000598	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	2.46e-05	0.000594	CbGpPWpGaD
Zuclopenthixol—DRD1—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	2.42e-05	0.000584	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	2.4e-05	0.000579	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	2.4e-05	0.000579	CbGpPWpGaD
Zuclopenthixol—DRD1—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	2.38e-05	0.000575	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	2.36e-05	0.00057	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	2.36e-05	0.00057	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	2.35e-05	0.000569	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	2.35e-05	0.000569	CbGpPWpGaD
Zuclopenthixol—DRD1—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	2.34e-05	0.000567	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	2.31e-05	0.000558	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	2.31e-05	0.000558	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	2.28e-05	0.000552	CbGpPWpGaD
Zuclopenthixol—DRD1—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	2.18e-05	0.000526	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	2.15e-05	0.000519	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	2.15e-05	0.000519	CbGpPWpGaD
Zuclopenthixol—DRD1—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	2.13e-05	0.000514	CbGpPWpGaD
Zuclopenthixol—DRD5—Signaling Pathways—IL2—acquired immunodeficiency syndrome	1.89e-05	0.000457	CbGpPWpGaD
Zuclopenthixol—DRD5—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	1.88e-05	0.000455	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	1.82e-05	0.000441	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	1.8e-05	0.000434	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	1.79e-05	0.000434	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	1.79e-05	0.000433	CbGpPWpGaD
Zuclopenthixol—DRD2—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	1.77e-05	0.000428	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	1.77e-05	0.000427	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	1.76e-05	0.000426	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	1.76e-05	0.000425	CbGpPWpGaD
Zuclopenthixol—HTR2A—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	1.74e-05	0.000421	CbGpPWpGaD
Zuclopenthixol—HRH1—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	1.74e-05	0.00042	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	1.73e-05	0.000418	CbGpPWpGaD
Zuclopenthixol—ADRA1A—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	1.7e-05	0.000412	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	1.64e-05	0.000397	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	1.63e-05	0.000395	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	1.62e-05	0.000391	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	1.61e-05	0.00039	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	1.61e-05	0.000389	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	1.61e-05	0.000388	CbGpPWpGaD
Zuclopenthixol—ADRA2A—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	1.58e-05	0.000383	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	1.58e-05	0.000383	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	1.58e-05	0.000382	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	1.58e-05	0.000381	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	1.55e-05	0.000374	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	1.47e-05	0.000355	CbGpPWpGaD
Zuclopenthixol—HTR6—Signaling Pathways—IL2—acquired immunodeficiency syndrome	1.46e-05	0.000353	CbGpPWpGaD
Zuclopenthixol—HTR6—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	1.45e-05	0.000351	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	1.44e-05	0.000348	CbGpPWpGaD
Zuclopenthixol—DRD1—Signaling Pathways—IL2—acquired immunodeficiency syndrome	1.26e-05	0.000304	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Metabolism—ALB—acquired immunodeficiency syndrome	1.25e-05	0.000303	CbGpPWpGaD
Zuclopenthixol—DRD1—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	1.25e-05	0.000302	CbGpPWpGaD
Zuclopenthixol—DRD5—Signaling Pathways—IL6—acquired immunodeficiency syndrome	1.11e-05	0.000269	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—IL2—acquired immunodeficiency syndrome	9.49e-06	0.000229	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	9.44e-06	0.000228	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—IL2—acquired immunodeficiency syndrome	9.34e-06	0.000226	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—IL2—acquired immunodeficiency syndrome	9.32e-06	0.000225	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	9.29e-06	0.000225	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	9.27e-06	0.000224	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—IL2—acquired immunodeficiency syndrome	9.14e-06	0.000221	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	9.1e-06	0.00022	CbGpPWpGaD
Zuclopenthixol—HTR6—Signaling Pathways—IL6—acquired immunodeficiency syndrome	8.58e-06	0.000208	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—IL2—acquired immunodeficiency syndrome	8.5e-06	0.000205	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	8.45e-06	0.000204	CbGpPWpGaD
Zuclopenthixol—CYP2D6—Metabolism—ALB—acquired immunodeficiency syndrome	8.17e-06	0.000197	CbGpPWpGaD
Zuclopenthixol—DRD1—Signaling Pathways—IL6—acquired immunodeficiency syndrome	7.39e-06	0.000179	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—IL6—acquired immunodeficiency syndrome	5.58e-06	0.000135	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—IL6—acquired immunodeficiency syndrome	5.49e-06	0.000133	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—IL6—acquired immunodeficiency syndrome	5.48e-06	0.000132	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—IL6—acquired immunodeficiency syndrome	5.37e-06	0.00013	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—IL6—acquired immunodeficiency syndrome	4.99e-06	0.000121	CbGpPWpGaD
